Drug Combination Details
| General Information of the Combination (ID: C18809) | |||||
|---|---|---|---|---|---|
| Name | Platycodin D NP Info | + | Sorafenib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Prostate cancer
[ICD-11: 2C82]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Ubiquitination | AKT1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | ||
| DU145 | CVCL_0105 | Prostate carcinoma | Homo sapiens | |||
| In-vivo Model | PC3 cells (shRNA-FOXO3a cells and MOCK cells) were injected subcutaneously into the left inguinal area of nude mice (BALB/c, nu/nu, male, 6-8 weeks old). | |||||
| Experimental
Result(s) |
The combination of Platycodin D and sorafenib may exert potent anti-cancer effects specifically via FOXO3a. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Combined Anti-Cancer Effects of Platycodin D and Sorafenib on Androgen-Independent and PTEN-Deficient Prostate Cancer. Front Oncol. 2021 May 7;11:648985. | |||
